Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
brand:
None (3) ·
5HT1a (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Melatonin receptor agonist (2) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA-receptor antagonism (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Selective M1 muscarinic antagonist (1) ·
Source of DMT-class tryptamines (1) ·
Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) ·
Source of [[DMT|N,N-dimethyltryptamine]] (1) ·
TBD (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) ·
µ-opioid agonism (1)
None (50) ·
Antimanic, Antidepressive, Antisuicide (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Pain, cough, disquiet (1) ·
'"`UNIQ--vote-0000152F-QINU`"' (1) ·
'"`UNIQ--vote-00001582-QINU`"' (1)
None (52) ·
1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID (1) ·
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
None (52) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)
None (52) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (53) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 55 results in range #1 to #55.


